The medicine, Blincyto, contains Blinatumomab as an active ingredient with inactive ingredients citric acid monohydrate, lysine hydrochloride, polysorbate 80, trehalose dihydrate, and sodium hydroxide
| Founded year: | Not set |
| Funding rounds: | Not set |
| Total funding amount: | Not set |